Antiarrhythmics

Two patients, both newly identified as candidates for a rhythm-control conversation, sit at opposite points in how far atrial structural remodeling has progressed. One is six weeks into her diagnosis; her atrium hasn't yet reorganized around the arrhythmia. The other has carried his for two years, and the reorganization is already complete. The pharmacology doesn't change — the question of whether it can still work does.

Two ICD shocks in six weeks for sustained monomorphic VT, on top of already-optimized heart failure therapy — the harder question isn't whether he needs an antiarrhythmic added, it's which one his QTc and his kidneys can actually tolerate.

A single patient, eight months into a rate-control strategy that is quietly failing. The disagreement isn't about whether the next drug works — it's about whether a drug's decades-old bad reputation is really about the drug itself, or about how it used to be dosed.

A paramedic with symptomatic paroxysmal AF and a history of myocarditis is offered two first-line paths — years of amiodarone, or a single procedure now — and the real disagreement in the room is about what the drug itself would actually cost her.

Digoxin alone isn't controlling her atrial fibrillation. Beta-blockade, the usual next step, is relatively contraindicated by her airway disease — leaving verapamil as the more defensible first move, though not a risk-free one.

Three converging cardiovascular risk factors, but no confirmed structural or ischemic heart disease — the case depends on how much testing is needed before a Class IC agent can safely be started.

L.H.'s first echocardiogram, ordered after her new atrial fibrillation diagnosis, put her ejection fraction at 43 percent — above the number most guidelines use to rule out one class of rate-control drug, but not clearly normal either.

A locksmith in his late sixties, two self-terminating atrial fibrillation episodes in three months, and hypertensive structural change nowhere near what shaped either drug's own worst reputation. The choice turns less on which drug controls rhythm better today than on which one he can safely carry for decades.

Years of stable digoxin dosing for rate control, now complicated by a new amiodarone prescription and a well-documented interaction that roughly doubles digoxin levels within weeks. The direction of the risk isn't in question — how precisely to respond to it is.

A beta-blocker that controlled her heart rate but left her too fatigued to work, and an alternative with genuine placebo-controlled evidence behind it — complicated by a real safety conversation the efficacy data alone doesn't settle.

A large, real-world study now supports starting sotalol outside the hospital for appropriately selected patients — but a renal-driven dosing change is exactly the kind of complication that study's population mostly didn't include.

His family has made every decision comfort-focused care usually requires. Nobody had yet mentioned the device in his chest that could still shock him on the way out.

A single patient whose paroxysmal AF is textbook for pill-in-pocket therapy — except for one echocardiographic finding that isn't officially disqualifying, and isn't officially reassuring either.

A single patient whose new atrial fibrillation is being rate-controlled by a drug chosen before anyone confirmed why her heart rate wouldn't come down, and the diagnosis that answered that question has reopened the drug choice.

A single patient whose ECG pattern is classic for a benign, treatable diagnosis, with one imaging study left to complete before the standard drug for that diagnosis is started for the long term.